IRL 752

Drug Profile

IRL 752

Alternative Names: IRL752

Latest Information Update: 24 Nov 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Integrative Research Laboratories
  • Class Antidementias; Small molecules
  • Mechanism of Action Central nervous system stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Phase II Dementia
  • Phase I Attention-deficit hyperactivity disorder

Most Recent Events

  • 05 Oct 2017 IRLAB receives approval from the Finnish MPA for a phase II trial in Finland
  • 04 Oct 2017 Phase-II clinical trials in Dementia in Scandinavia
  • 29 Feb 2016 Swedish Medical Products Agency (MPA) and the Regional Ethical Review Board, Uppsala, approve initiation of phase I trials for IRL 752 in Attention-deficit hyperactivity disorder and Dementia
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top